Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708061 | 0.92 | SMN1; SMN2 (0.61) | MCHR1SMN1; SMN2DRD4DRD2ENPP2 | |
| Hydrochloric Acid SCHEMBL11073301 | 0.91 | SMN1; SMN2 (0.63) | MCHR1SMN1; SMN2DRD4DRD2ENPP2 | |
| SCHEMBL10058617 | 0.84 | PDE3B (0.48) | MCHR1DRD4DRD2MEN1KMT2A | |
| SCHEMBL10606808 | 0.82 | MCHR1 (0.60) | MCHR1SMN1; SMN2DRD4DRD2MEN1 | |
| SCHEMBL10608988 | 0.81 | MEN1 (0.59) | MCHR1SMN1; SMN2DRD4MEN1POLB | |
| SCHEMBL3886322 | 0.81 | MCHR1 (0.59) | MCHR1SMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL10608615 | 0.81 | MCHR1 (0.59) | MCHR1SMN1; SMN2DRD4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10608932 | 0.81 | MCHR1 (0.58) | MCHR1SMN1; SMN2DRD4DRD2MEN1 | |
| SCHEMBL5884214 | 0.80 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL7260093 | 0.80 | MCHR1 (1.00) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | MERCK SHARP & DOHME B.V. (NL) | 2002-04-04 | — | — | US | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| WO-1999043647-A1 | DERIVATIVES OF AZETIDINE AND PYRROLIDINE | AKZO NOBEL N.V. (NL) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
| EP-0147909-B1 | ARYLOXY-N-(AMINOALKYL)-1-PYRROLIDINE AND PIPERIDINE CARBOXAMIDES AND CARBOTHIOAMIDES HAVING ANTIARRHYTHMIC ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4547514-A | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-10-15 | — | — | US | disclosed |
| EP-0147909-A1 | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | TPH1, TPH2, HTR1D | MCHR1 305/4885SMN1; SMN2 1595/4885DRD4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.